A longitudinal study of the persistence of increased creatinine and concordance between kidney biomarkers in cats and dogs.

Vet J. October 2021;276(0):105729.

H T Michael¹, R M MACK², E Hegarty³, D J McCrann⁴, G F Grauer⁵

¹ IDEXX, 1 IDEXX Drive, Westbrook, ME 04092, USA. Electronic address: helen-michael@idexx.com.; ² IDEXX, 1 IDEXX Drive, Westbrook, ME 04092, USA. Electronic address: rebekah-mack-gertig@idexx.com.; ³ IDEXX, 1 IDEXX Drive, Westbrook, ME 04092, USA.; ⁴ IDEXX, 1 IDEXX Drive, Westbrook, ME 04092, USA.; ⁵ College of Veterinary Medicine, Kansas State University, A-111 Mosier Hall, Manhattan, KS 66506-5802, USA.

Abstract

Kidney disease causes morbidity and mortality in dogs and cats. Serum creatinine concentration is an important surrogate marker for glomerular filtration rate (GFR). However, it is not always sensitive to small decreases in kidney function. Efforts to identify additional, more sensitive surrogate markers of GFR to improve detection of early kidney disease has led to the use of symmetrical dimethylarginine (SDMA) in veterinary medicine. There is insufficient information about the behavior of creatinine after an increase and the expected behavior of creatinine and SDMA in these cats and dogs. This study assesses the probability of persistence of increases in creatinine and the subsequent behavior of creatinine and SDMA in animals with persistently increased creatinine. For enrollment, three paired SDMA and creatinine concentrations were required: baseline (T0) with creatinine and SDMA at or below the upper reference limit (URL), T1, and T2 0.5-18 months after T1. The study included 4517 cats and 4576 dogs with increased T1 creatinine concentrations and 54,295 cats and 125,403 dogs with T1 creatinine at or below the URL. The probability of a persistently increased creatinine at T2 was approximately 58% for cats and 49% for dogs after a T1 increase. For animals without a T1 increase the probability of increased creatinine at T2 was only 7% for cats and 3% for dogs. For cats and dogs with persistently increased Cr, the probability of an increased SDMA concentration at T1 was 70-75%. By 24 months, that probability rose to 94% for cats and 88% for dogs.

Keywords

Biomarker; Data study; Kidney disease; Symmetric dimethylarginine;

Article Tools:

Medline

Email to me

Archives Highlights:

Diagnostic value of liver function tests and ultrasonography in dogs with suspected congenital portosystemic shunts.
Fasting ammonia (FA) had the best combined sensitivity and specificity (77.4 and 93.3%, respectively) to diagnose congenital portosystemic shunt (cPSS). The sensitivity and negative predictive value were 100.0% for paired serum bile acids (SBA), making paired SBA the best test to exclude cPSS in this population. Sensitivity and specificity of abdominal ultrasound were 80.8 and 90.0%, respectively.

Canine coat pigmentation genetics: a review.
Some genes involved in canine pigmentation have been linked to aural, visual, and neurological impairments. In this paper, we discuss coat colour phenotypes in the domestic dog, the genes and variants responsible for these phenotypes, and any proven coat colour-associated health effects.

Canine Pelvic Limb Amputation
Some amputations are necessary due to the pet owner’s financial constraints. However, surgeons are encouraged to exhaust all options prior to limb amputation while also educating owners about the risks, complications, and prognosis for each specific clinical case.

Upper and lower respiratory airway complaints among female veterinary staff.
Atopy was seen in 31% of the 109 female participants. Symptoms of rhinoconjunctivitis were the most frequent complaints (n = 92; 84%). Symptoms of upper and lower airways were highly correlated and an asthma diagnosis was confirmed in 11% of participants. Modelling revealed that sensitization against cats/dogs was a significant risk factor for respiratory symptoms of upper [odds ratio (OR) 4.61] and lower airways (OR 5.14), physician-confirmed rhinoconjunctivitis (OR 13.43), and asthma (OR 9.02) in assistant staff of small-animal practices.

Clinical Efficacy and Safety of Malarone^®, Azithromycin and Artesunate Combination for Treatment of Babesia gibsoni in Naturally Infected Dogs.
The dogs received combined therapy with Malarone (13.5 mg/kg PO q24 h), azithromycin (10 mg/kg PO q24 h), and artesunate (12.5 mg/kg PO q24 h) for 10 days. The combined treatment improved hematology and biochemical parameters to the reference range gradually during the first 14 days, resulting in stable values until day 56 after treatment. No clinically apparent adverse effects were reported during treatment and monitoring. No relapses of parasitemia were detected in control days 180, 360, 540, and 720 in all dogs.